Clinical Trial Update: The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating olaparib in combination with abiraterone and prednisone in metastatic hormone-receptor-mutant prostate cancer is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Olaparib (Olaparib)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Hongqian Guo | Conditions: Prostate Cancer, Prostate Carcinoma | Phase 2 | Status: UNKNOWN